Mann B S, Moslehuddin K S, Owen R T, Clayton A R, Rohatgi K K, Sud P, Vaddadi K S
Pharmatherapeutica. 1985;4(6):387-92.
An open, multi-centre study was carried out in 69 patients with an acute psychotic episode to assess the efficacy and side-effects of treatment with oral zuclopenthixol dihydrochloride. Patients were treated until the acute episode was considered terminated by the clinician and, although dosage could be adjusted to allow optimum clinical response, the majority received 25 mg zuclopenthixol dihydrochloride 3-times daily throughout the trial period. Assessments were made before and during treatment using the BPRS and CGI rating scales and a check-list of side-effects. The results showed that 55 (80%) patients had a successful response to treatment. Almost half (33) of the patients responded fully to the drug within 3 weeks and by the end of 5-weeks' treatment this had increased to over 70% (49). A further 6 patients responded after 6 to 9 weeks of treatment. The drug was generally well tolerated and the majority of patients had either no side-effects or side-effects which did not overtly affect performance.
一项针对69例急性精神病发作患者的开放性多中心研究开展，以评估口服二盐酸珠氯噻醇治疗的疗效和副作用。患者接受治疗直至临床医生认为急性发作结束，尽管可调整剂量以获得最佳临床反应，但在整个试验期间，大多数患者每日3次服用25mg二盐酸珠氯噻醇。在治疗前和治疗期间使用简明精神病评定量表（BPRS）、临床总体印象量表（CGI）以及副作用清单进行评估。结果显示，55例（80%）患者治疗反应良好。近一半（33例）患者在3周内对药物完全反应，至5周治疗结束时，这一比例增至70%以上（49例）。另有6例患者在治疗6至9周后出现反应。该药物总体耐受性良好，大多数患者无副作用或副作用未明显影响其行为表现。
